aCGT Vector’s focus is Cellular Therapy, rapidly evolving as a therapeutic procedural approach that brings promise to patients, their families and clinicians; for the treatment of rare diseases, most critically cancer. Less than 5% of patients suffering from rare diseases today have any therapeutic option available to them.
aCGT Vector’s Cellular Therapy procedures will involve collecting patients‘ own immune cells and bringing them safely to its GMP facility inside the hospital for process engineering and potential exponential expansion in volume, to make these immune cells more strategically effective, before being administered back into the same patient, on average up to 4 weeks later.
We have the infrastructure and a team of specialists across the cell therapy life cycle, who will work with you enabling the best possible results.
The cell therapy industry has seen aggressive growth in part due to successful CAR-T therapies offering durable cures to patients with primarily liquid tumours. Learnings from CAR-T therapy have led to engineering modifications for the next generation of cell therapy products using a wider range of cell types (TCR, NK, TIL, MIL), allogeneic (“off the shelf”) approaches, and effective treatments for solid tumours. While the vast majority of the current cell therapy indications centre around oncology, other therapeutic areas such as autoimmune, cardiology, and neurology continue to advance.
The aCGT Vector Cell Therapy team is actively engaged in projects across the advanced therapeutics portfolio. Recently, Mesenchymal stem cell therapy is also showing promising impact as a bridge treatment option in alleviating severe symptoms of COVID-19. aCGT Vector is working to become a partner to many COVID-19 treatments across its portfolio and is committed to supporting safe and effective treatments for this global pandemic.
Autologous Cellular Therapy is the safest and most certain approach being taken today, where the patients’ own immune cells are removed, transformed and potentially expanded in volume using aCGT Vector’s s modern closed-ex-vivo-system technology and state of the art GMP facility. The modified immune cells are then re-infused back into the same patient to target and treat their own rate disease. This entirely avoids any and all risks of their own immune system identifying these incoming cells as foreign and rejecting them which could prove fatal to often immune system compromised patients
aCGT Vector’s inter-connected and digitalised ATMP PODs located in international cellular therapy hospital centres of excellence will capture data that will play a pivotal role in improving patient outcomes.
aCGT Vector, as much a data company as a cellular therapy company, is building a cloud-based proprietary digital platform that securely captures and aggregates patient outcome data to facilitate analysis and scrutinisation; from the patient with rare disease presenting to the hospital, cell collection, cell selection, cell transformation and expansion in cell volume, and ultimately to cellular therapy procedure being administered back to the patient and health monitoring, to capture important data that can be fed back to improve the following procedures for patients.
This data will drive cellular therapy procedure improvement
Tony Holohan joins board of Irish cell therapy company aCGT Vector Founded in 2020, aCGT Vector is a member of the Irish Government-funded Healed Consortium.
The future of the delivery of Development of Cell and Gene Therapies SAN FRANCISCO & DUBLIN–(BUSINESS WIRE)–Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene
The Future of the Delivery of Modern Medicine in St. James’s Hospital and the Trinity College Dublin Clinical Research Facility in Dublin 7-8th July. Thanks
Patients requiring CAR-T immunotherapy previously had to travel to UK for treatment A Co Mayo man has become the first patient in Ireland to receive groundbreaking cell therapy treatment
Allogeneic products may dominate the cell therapy sector thanks to tech and cost advantages but there will always be room for autologous treatments, say experts.
The Road To 50 States! Discovering the Future of Healthcare After achieving what was previously thought impossible – 25 European countries in 25 days –
© aCGT Vector – All Rights Reserved
aCGT Vector DAC,
The Mill Enterprise Hub,
Newtown Link Road,
Greenhills, Drogheda,
Co. Louth, A92 CD3D,
Republic of Ireland,
Europe
+353 864667889